Candidate for new corona drug “Administer through clinical trial” 18:42, May 19, Japan Medical Association
Regarding the candidate drug for the new coronavirus, an expert meeting of the Japan Medical Association made an urgent recommendation that it should be administered with careful safety through clinical trials, etc., rather than granting special approval in a hurry. I put it out.
Since no specific medicine for the new coronavirus is available at this time, other drugs such as "Abigan", a therapeutic drug for new influenza, are being administered to patients in a clinical trial framework.
Against this backdrop, an expert meeting of the Japan Medical Association made an urgent recommendation on therapeutic drug development on the 18th.
In the recommendation, "I am aware that special measures to speed up approval of a new drug because it is an emergency, but I must be convinced that insufficient proof of safety and efficacy is sufficient." As some patients will recover, it requires appropriate clinical trials in many patients.
On top of that, we should not forget the drug damage such as thalidomide that caused serious damage to the baby, rather than granting special approval without hurrying, clinical trials etc. until scientifically proven to be safe and effective. Should be administered through.
Norihiro Kokuchi, director of the National Center for Global Health and Medicine, who was involved in making recommendations, said, "Some existing drugs do not have enough information on side effects. Once approved, it will be difficult to confirm whether they are effective or not. We should proceed in the right way. ”